Additionally, various natural products and drugs have been explored as potential therapeutic agents targeting KCs or macrophages to treat NAFLD, including CCR2/CCR5 antagonists and galectin-3 inhibitors. Here, LGALS3 is linked to metabolic dysfunction-associated steatotic liver disease.